Stress response mediator activating transcription factor 3 (ATF3) engages in diverse oncogenic pathways including the androgen receptor signaling essential for prostatic proliferation. In line with frequent downregulation of ATF3 expression in human prostate cancers, we have provided the first genetic evidence supporting the role of ATF3 as a tumor suppressor in a subset of prostate cancers with PTEN dysfunction.
|Original language||English (US)|
|Journal||Molecular and Cellular Oncology|
|State||Published - Jan 2 2016|
- prostate cancer
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research